EE9800105A - Dendriitrakke stimuleeriv faktor - Google Patents

Dendriitrakke stimuleeriv faktor

Info

Publication number
EE9800105A
EE9800105A EE9800105A EE9800105A EE9800105A EE 9800105 A EE9800105 A EE 9800105A EE 9800105 A EE9800105 A EE 9800105A EE 9800105 A EE9800105 A EE 9800105A EE 9800105 A EE9800105 A EE 9800105A
Authority
EE
Estonia
Prior art keywords
stimulating factor
dendritic cell
cell stimulating
dendritic cells
cells
Prior art date
Application number
EE9800105A
Other languages
English (en)
Estonian (et)
Inventor
D. Lyman Stewart
R. Mckenna Hilary
H. Lynch David
Brasel Kenneth
Maraskovsky Eugene
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of EE9800105A publication Critical patent/EE9800105A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EE9800105A 1995-10-04 1996-10-03 Dendriitrakke stimuleeriv faktor EE9800105A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53914295A 1995-10-04 1995-10-04
PCT/US1996/015990 WO1997012633A1 (fr) 1995-10-04 1996-10-03 Facteur de stimulation de cellules dendritiques

Publications (1)

Publication Number Publication Date
EE9800105A true EE9800105A (et) 1998-10-15

Family

ID=24149974

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800105A EE9800105A (et) 1995-10-04 1996-10-03 Dendriitrakke stimuleeriv faktor

Country Status (23)

Country Link
EP (1) EP0871487B1 (fr)
JP (1) JP3631496B2 (fr)
KR (2) KR100676792B1 (fr)
CN (1) CN1172718C (fr)
AT (1) ATE432085T1 (fr)
AU (1) AU697539B2 (fr)
BR (1) BR9610802A (fr)
CA (1) CA2232865A1 (fr)
CZ (1) CZ97798A3 (fr)
DE (1) DE69637942D1 (fr)
EA (1) EA199800272A1 (fr)
EE (1) EE9800105A (fr)
ES (1) ES2323818T3 (fr)
IS (1) IS4703A (fr)
LV (1) LV12085B (fr)
NO (1) NO981374L (fr)
NZ (1) NZ321039A (fr)
PL (1) PL187329B1 (fr)
RO (1) RO120579B1 (fr)
SI (1) SI9620116A (fr)
SK (1) SK40898A3 (fr)
TR (1) TR199800607T1 (fr)
WO (1) WO1997012633A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
AUPO388396A0 (en) * 1996-11-27 1996-12-19 Ludwig Institute For Cancer Research Cellular adjuvant
WO1998057655A1 (fr) * 1997-06-17 1998-12-23 Immunex Corporation Procede permettant d'ameliorer la tolerance immunitaire peripherique specifique a un antigene
FR2782524B1 (fr) * 1998-08-21 2002-07-19 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2775692B1 (fr) * 1998-03-03 2000-06-16 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en) 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
WO1999062537A1 (fr) * 1998-06-04 1999-12-09 The Rockefeller University Procedes et agents permettant la modulation de la reponse immunitaire et de l'inflammation par modulation des proteines membranaires des monocytes et des cellules dendritiques
US6291661B1 (en) 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
AU5741699A (en) * 1998-08-27 2000-03-21 Universitatsklinikum Freiburg Low-molecular fragments of hyaluronic acid for the preparation of vaccines
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
WO2001009303A2 (fr) * 1999-07-30 2001-02-08 Vical Inc. Polynucleotide codant pour un ligand flt-3 comme activateur de vaccin a base de polynucleotides
AU1358501A (en) * 1999-11-03 2001-05-14 Powderject Vaccines, Inc. Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
WO2001062275A1 (fr) * 2000-02-24 2001-08-30 The Board Of Trustees Of The Leland Stanford Junior University Traitement adjuvant par activation in vivo de cellules dendritiques
ES2254408T4 (es) * 2000-04-25 2007-10-01 Immunex Corporation Procedimiento de tratamiento de tumores usando terapia fotodinamica.
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
WO2002040044A2 (fr) * 2000-11-17 2002-05-23 Immunex Corporation Recrutement par chimiotactisme de cellules dendritiques pour renforcer l'immunisation
DK2322603T3 (da) * 2001-09-06 2020-01-27 Northwest Biotherapeutics Inc Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
KR100490308B1 (ko) * 2002-02-25 2005-05-17 크레아젠 주식회사 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
PL377028A1 (pl) * 2002-03-26 2006-01-23 Immunex Corporation Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) * 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) * 2005-04-08 2008-05-15 Tgc Biomics Gmbh Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko) 2006-10-11 2008-04-01 재단법인서울대학교산학협력재단 Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko) 2011-05-20 2013-05-15 충남대학교산학협력단 마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
WO2018013820A1 (fr) 2016-07-13 2018-01-18 Ohio State Innovation Foundation Plateformes et procédés pour l'optimisation de la présentation de l'antigène par l'hôte, et immunité anti-tumorale et anti-infectieuse de l'hôte

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US826250A (en) 1905-12-20 1906-07-17 Albert Huck Switch for toy railways.
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0790307A1 (fr) 1986-12-16 1997-08-20 Gist-Brocades B.V. Clonage et expression moléculaire de IL-3 humain
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
WO1989003881A1 (fr) 1987-10-30 1989-05-05 Immunex Corporation Analogues non glycosyles de facteurs humains de stimulation de colonies
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP1241258A3 (fr) 1989-10-16 2003-12-10 Amgen Inc. Facteur de stimulation de cellules souches
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CA2122141C (fr) 1991-10-23 2007-07-17 Shelly Heimfeld Methode de multiplication selective de cellules souches
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells

Also Published As

Publication number Publication date
CZ97798A3 (cs) 1999-02-17
SK40898A3 (en) 1999-04-13
EA199800272A1 (ru) 1998-10-29
EP0871487A4 (fr) 2004-09-01
JP3631496B2 (ja) 2005-03-23
KR100676792B1 (ko) 2007-02-02
AU7392296A (en) 1997-04-28
NO981374L (no) 1998-06-03
EP0871487A1 (fr) 1998-10-21
CA2232865A1 (fr) 1997-04-10
IS4703A (is) 1998-03-26
KR19990063818A (ko) 1999-07-26
LV12085B (en) 1998-09-20
CN1172718C (zh) 2004-10-27
LV12085A (lv) 1998-07-20
RO120579B1 (ro) 2006-04-28
BR9610802A (pt) 1999-07-13
PL325964A1 (en) 1998-08-17
NZ321039A (en) 2001-03-30
NO981374D0 (no) 1998-03-26
ES2323818T3 (es) 2009-07-24
JPH11513389A (ja) 1999-11-16
WO1997012633A1 (fr) 1997-04-10
KR20040079421A (ko) 2004-09-14
KR100514957B1 (ko) 2005-11-25
EP0871487B1 (fr) 2009-05-27
AU697539B2 (en) 1998-10-08
SI9620116A (sl) 1999-08-31
TR199800607T1 (xx) 1998-06-22
CN1229359A (zh) 1999-09-22
ATE432085T1 (de) 2009-06-15
DE69637942D1 (de) 2009-07-09
PL187329B1 (pl) 2004-06-30

Similar Documents

Publication Publication Date Title
NO981374D0 (no) Dendrittcellestimulerende faktor
NO986173L (no) FremgangsmÕte for aktivering av dendrittceller
AU2953895A (en) Multi-stage cascade boosting vaccine
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
Holden et al. Human and mouse embryonal carcinoma cells in culture share an embryonic antigen (F9)
DE69418856D1 (de) Targeting von immunogenen durch lysosomen
DK66692A (da) En mammal cytokin, il-11
ATE195875T1 (de) Spezifische modulationen des immunsystems
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
MX9603431A (es) Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.
DK0843731T3 (da) Adenovirusvektorer til genterapi
ATE283354T1 (de) Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
AU5573196A (en) A pluripotent vaccine against enveloped viruses
HK1025220A1 (en) Novel saponin compositions and uses thereof
Alaba et al. Specific induction of syngeneic cytotoxic T lymphocytes by solubilized tumor antigen: fractionation of the specific R-MuLV-induced leukemia antigen.
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.
London Reovirus-induced perturbations of mucosal T and B lymphocyte populations.
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
Szostak Rekombinante Bakteriunhuellen als Impfstoffe.
MX9606317A (es) Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos.
Faherty CLONAL ANALYSIS OF AUTOREACTIVE HELPER T CELLS.
MX9800821A (es) Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata.